Drugs / Salmeterol/fluticasone
last change Jul 2017 re-read 2 minutes ago

Salmeterol/fluticasone

Developed for
chronic obstructive pulmonary disease

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT02603393 Comparator Nov 2015 → Jul 2017 chronic obstructive pulmonary disease Novartis Pharmaceuticals Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Salmeterol/fluticasone ClinicalTrials.gov intervention name — accepted as the source's own label NCT02603393
Known as salmeterol/fluticasone propionate Salmeterol/fluticasone propionate dry inhalation powder delivered via Accuhaler™” NCT02603393
Route Inhaled “Salmeterol/fluticasone propionate dry inhalation powder delivered via Accuhaler™” NCT02603393